China Yongxin Pharmaceuticals, Inc. (fka CYXN)

[Renee]

CYXN revoked:

http://www.sec.gov/litigation/admin/2012/34-68346.pdf

[sidedraft]

SUSPENDED:

The U.S. Securities and Exchange Commission announced the temporary suspension of trading in the securities of the following issuers, commencing at 9:30 a.m. EDT on October 24, 2012 and terminating at 11:59 p.m. EST on November 6, 2012:
• China Voice Holding Corp. (CHVC)
• China Yongxin Pharmaceuticals, Inc. (CYXN)
• Creative Technologies Holdings, Inc. (CRTV)
• Crestek, Inc. (CRST)
• Crys*Tel Telecommunications.com, Inc. (n/k/a Fleet Management Solutions,
Inc.) (FLMG)
• CSI Computer Specialists, Inc. (CSIS)
• CST Entertainment, Inc. (n/k/a Legacy Holding, Inc.) (LGYH)

http://www.sec.gov/litigation/suspensions/2012/34-68092.pdf

SEC Order:

http://www.sec.gov/litigation/suspensions/2012/34-68092-o.pdf

[Deanhan1]

completely dead company

[IPO$]

a Big 4 auditor is key to these chinese stocks

[presence]

My God. WTF has come of this POS? Any idea when they report earnings? Just another China company that went into the crapper.

[presence]

Yeah, I wish I would have dumped even in the $3's. Now, I'm a bagholder at these levels. I'm hoping something turns this S/P around soon. It may take a year or two. Hopefully, they'll wake up and see just what the hell they did. Good luck, Bob.

[Bobwins]

Finally dumped the last of my shares. As soon as mgmt pulled the fast one and converted their shares in violation of previous agreements they had made, I should have dumped. Holding only increased the pain. Poor IR, poor mgmt decisions to favor insiders, mediocre results.

[presence]

Is this thing ever gonna show life again? Think they're another China scam or bust?

[presence]

Yeah, it seems that way. all the way from my buy price of the equivalent of $7 plus. What a let-down. It started when they began to issue shares to family members...then the R/S to nowhere.

[IPO$]

this one is dead...MSAH is an OTCBB company also producing ginger. Business is good according to 10-Q's.

[Bobwins]

Unfortunately I still am. As soon as I saw that insider PP for way below market, I should have run. The mgmt doesn't get it. Also this is a changing, competitive market and these guys are trying to remake themselves from wholesale to retail. Going to have some growing pains. I keep hoping that they pull this off but so far the results are mixed.

[Bob Stocks]

You still holding this Bobwins?

[presence]

This just keeps on getting better and better. Barely above $3.00. Dayumn!

[bUrRpPPP!]

OMG....almost spit out my beer on that one.....LMAO!

[Bobwins]

Lurk harder and buy some shares so I can get out!

Everything looks good here except the mgmt. The concept is good, the timing is right for expanding retail pharmacies but the way undermarket financing for friends and family really torpedoed the share price and then they did the weird 1 for 12 split. I am way down but volume sucks. also they did some weird things with insiders converting shares. They were supposed to be limited but they converted them all at once. I don't think they understand that screwing the common shareholders is not in their best interest.

Bobwins

[bUrRpPPP!]

Lurking.....

[Bobwins]

reverse split. More shareholder friendly actions.....NOT!

Reverse Stock Split

Effective on May 24, 2010, China Yongxin Pharmaceuticals Inc. (the "Company") effectuated a reverse stock split with a ratio of 1-for-12, whereby each twelve
(12) issued and outstanding shares of the common stock of the Company, par value $0.001 per share ("Common Stock") shall be combined into one (1) share of Common Stock (the "Reverse Split"), pursuant to the Certificate of Amendment of the Certificate of Incorporation that the Company filed with the State of Delaware's Secretary of State ("Certificate of Amendment"). As described more fully in the Definitive Information Statement filed by the Company with the Securities and Exchange Commission ("SEC") on February 22, 2010, a reverse split of the Common Stock, with a ratio within a range of 1-for-10 to 1-for-15 (the "Reverse Split Range") and with the exact ratio within the Reverse Split Range to be determined by the Company's Board of Directors (the "Board"), was adopted and approved by written consent dated February 8, 2010 by the Board, the holders of a majority of the shares of Common Stock and Series A Convertible Preferred Stock ("Series A Preferred Stock") then outstanding and entitled to vote (voting as a single class), and by the holders of a majority of our Series A Preferred Stock voting as a separate class. On April 28, 2010, the Board adopted and approved by written consent a 1-for-12 reverse split ratio and it authorized the Company's officers to file the Certificate of Amendment and take all other necessary steps in order to effect the Reverse Split.

Effective May 26, 2010, the Company's Common Stock will commence trading under a new OTC Bulletin Board trading symbol, "CYXND". The new trading symbol has been assigned by Financial Industry Regulatory Authority ("FINRA") in connection with the approval of the Reverse Split. The Company's trading symbol will revert to "CYXN" within 20 business days. The Company's Common Stock, on a split-adjusted basis, has a new CUSIP number of 16946Y 207. The Certificate of Amendment is filed as Exhibit 3.1 to this Current Report on Form 8-K ("Form 8-K") and incorporated herein by reference.

Bylaws Amendments

[Stream205]

US Senate steals CYXNs idea:

http://cnsnews.com/news/article/64663


http://www.breakoutinvestments.com/?q=node/520

[bolsheada]

Price jumped up to 0.69 yahoooo!

[bolsheada]

5 steady sessions in green. R we going to .7-.8 again?

[sdy]

Bounced off the 50DMA. Will this become a new trendline?

[presence]

Another red day in CYXN-land. Now I remember why I got out of this stock on December 31, when I lucked out holding to sell it until that final day when it went up to around .60. I escaped the red that time. Not this time. We'll see this bounce back...but not to the $1 we were hoping to see...at least not in the near future.

You're right, they are definitely going for the 1 for 10 when they easily could have done a 1 for 5 (or less) instead.

[Stream205]

Nonsense today:

I did not think they would have the nerve to repeat the January atrocity. Wrong.

I have held a position through this whole ordeal the last long months and still see a winner but today was a royal kick in the ass.

A disgrace.

No doubt they are gearing up for a 15-1 reverse, imo.

[presence]

Man, talk about a butt-kicking today. Hopefully, it will bounce and we prepare for the next steady leg up this week. But it can be chancy when you have a company that doesn't really care about issuing shares to a minimum. We'll see.

[Bobwins]

They did the same thing in January. I wrote them back then and said they may be helping friends and family but they were hurting investors who paid market prices for their stock. Apparently they didn't care. I complained to IR but they haven't heard from the company. She promised to forward my concerns to the CFO.

I doubt it does any good. I started to sell out in January but thought the business case was too good so I stopped. That was a mistake.

Bobwins

[Yompkee]

Unless they do something stupid like issue shares for .20 and warrants for .50. But how dumb would they have to be to do that? Oh right, that dumb.

[presence]

This is gonna get good. If not today, then next week. People are trying to bring it down like JADA and create dips that just ain't gonna happen, IMO. Too much value and potential in a .75-.80 stock. Enjoy the ride, folks!

[Bobwins]

Big pop +.17 to .85

Must be earnings from this week that caught someone's attention.

[presence]

Lovin' the Bid vs. Ask. Tight. This baby is set to run IMO.

[presence]

Well, based on the history of other profitable Chinese companies who have done the same, I look forward to the split. Yes, we'll see major swings with such a low float and OS/AS. But this company needs to hang with the players. And 2010 is the time to do that.

[presence]

Thanks for the clarification, Bob. Much appreciated. Well, let's hope they can put that out for the next fiscal year.

[Stream205]

CYXN: In-store medical diagnostic


In 2009 CYXN launched its new in store diagnostic system.

It took a while but its adding some serious value to CYXN.

The move from a drug wholesaler to a retailer (think WalGreens)is working out quite well.

Read about the program here.


From 2009:
http://www.breakoutinvestments.com/?q=node/520

[Bobwins]

They didn't make .15eps. They used a low share count of around 35 million but preferred shares have been converted to insiders, raising outstanding to 56million range. Made more like .09eps.

[morokoy]

On February 8, 2010, the Board of Directors adopted resolutions approving:
(1) approval of a reverse split of the company's common stock, par value $0.001 per share (the common stock) with a ratio within a range of 1-for-10 to 1-for-15 (the "Reverse Split Range"), with the exact ratio within the Reverse Split Range to be determined by the Board of Directors, ....etc...etc...

As of said date o/s was 56,648,923
O/S after 1-for-10 would be 5,664,893
O/S after 1-for-15 would be 3,776,596

[presence]

Just bought 22k at .65. Trying to get my last 8k filled to make an even 30k. This will explode into the dollar range by May or June. Anytime sooner is gravy.

Seriously, people, we're talking about a .65 stock making .15 a share. This is the next JADA, and because of their transparency, this could see $1.50 by summer. GLTA.

[Stream205]

CYXN: China YongXin Pharma. Buying more.


Their move into the retail sector is looking like a success.

28 more retail pharmacies in the pipeline.

Investors are going to like this story and todays PR is going over quite well.

http://finance.yahoo.com/news/China-Yongxin-Pharmaceuticals-prnews-3630437166.html?x=0&.v=11

[bradford86]

China Yongxin Pharmaceuticals Reports a 26% Increase in net Income for the 2009 Fiscal Year
Date : 04/06/2010 @ 8:00AM
Source : PR Newswire
Stock : China Yongxin Pharma (BB) (CYXN)
Quote : 0.65 0.0 (0.00%) @ 8:10AM



China Yongxin Pharmaceuticals Reports a 26% Increase in net Income for the 2009 Fiscal Year
China Yongxin Pharmaceuticals Reports a 26% Increase in net Income for the 2009 Fiscal Year

Year-end Reflects 37% Gross Profit Increase and Higher Gross Margins in Line With Refocus of Strategy Aimed at Higher Profit Retail Activities

PR Newswire

CHANGCHUN, China and LOS ANGELES, April 6

CHANGCHUN, China and LOS ANGELES, April 6 /PRNewswire-Asia/ --

China

Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN) (the "Company" or

"China Yongxin"), a fast-growing vertically-integrated health products company

in China, announced today its financial results for the fourth quarter and for

the year ended December 31, 2009.

Net income increased to $5.1 million in 2009, a 26% increase over $4.1

million in 2008. The increase was primarily related to higher margin sales and

was largely due to an increase in gross profit resulting from a change in the

composition of products sold, specifically, an increase in retail product

sales.

Revenues for the year ended 2009 decreased to $47.6 million, or 19.5% from

$59.1 million for 2008. The decrease in total revenue was due to the

transition of the Company's sales strategy, which, because of the uncertain

direction of the National Medical Policy, had been refocused from the

wholesale business to the retail and medical facilities sector. Although a

broader product portfolio and expanded marketing activities increased 2009

revenues from the Company's retail drug stores by approximately 27.9% over the

prior year, it was not sufficient to completely offset a decrease in revenue

from the Company's wholesale business, resulting in comparably lower total net

revenue. The substantial increase in revenue from the retail segment was

attributable to the addition of seven new retail drugstores in 2009, all

located in prime locations in the center of cities in Jilin province. To

further its new retail oriented sales strategy, the Company recently announced

its plan to open 28 new retail stores in 2010.

The Company also reported that basic and diluted earnings per share

increased to $0.15 for the year ended December 31, 2009 compared to $0.13 for

2008, based on 35.1 million and 31.2 million diluted weighted average shares

outstanding for 2009 and 2008, respectively, and 33.2 million and 31.2 million

basic weighted averages shares outstanding for 2009 and 2008, respectively.

These shares do not include approximately 1.67 million shares of preferred

stock owned by management, which is convertible into 10 million shares of

common stock.

The cost of goods sold for the year was $31.3 million, a significant

reduction compared to $47.2 million in the prior year. The decrease

corresponded with a decrease in sales volume. However, the Company was able

to reduce the cost of sales to net sales percentage from approximately 80% in

2008 to 66% in 2009 due to a change in product mix in which the proportion of

products sold with higher profit margins increased, such as cosmetics and

certain health and nutritional products. The Company improved its gross

profit margin by approximately 37.2% from $11.9 million in 2008 to $16.3

million in 2009. The increase in gross margins was primarily due to higher

margin retail and medical facilities sales.

Operating expenses for 2009 were $7.1 million, compared to $6.0 million in

2008. Selling expenses remained at approximately the same level, at $3.5

million. Management believes that in 2009 the Company prudently managed

utilities usage, transportation costs and sales people to effectively reduce

selling expenses and maintain its gross profit. General and administrative

expenses for 2009 increased approximately 43.0% to $3.6 million, compared to

$2.5 million in 2008. The majority of the increase was related to litigation

which was recently concluded.

Income from operations for 2009 was approximately $9.2 million, an

increase from the $5.9 million for 2008. Operating margins were 18% and 9.8%

for 2009 and 2008, respectively. A substantial portion of the increase

resulted from the expansion of the hospital market business and the increase

of the sale of the health care, cosmetic and nutrition products as well as

medical facilities sales.

Mr. Yongxin Liu, Chairman and Chief Executive Officer of the Company,

commented, "During 2007, the Company anticipated potential impact on its

wholesale distribution business resulting from uncertainty created by the

proposed National Medical Policy. We were pleased that the Chinese

government's August 18th issuance of China's Essential Drug List (the "EDL")

included over 300 commonly used pharmaceuticals that will be subsidized by the

government to provide easier access to all citizens. The Company is a

retailer or distributor of 295 of the products on the EDL. We continue to be

encouraged by the government's successful effort toward healthcare reform and

efforts to boost domestic spending."

Mr. Liu also added, "Our income growth in 2009 indicates that our business

model has placed the Company in a strong position to take positive advantage

of increased government support of health care and the continued expansion of

the economy in China." On March 9 2009, China Yongxin once again demonstrated

its "state-of-the-art" approach to providing retail drug customers with a high

level of service by formally launching its proprietary Electronic Diagnosis

System (the "System"), of which 20 Systems have been installed so far in chain

drugstores located in Changchun, Jilin. This proprietary system enables our

customers to remotely receive medical diagnosis and conveniently purchase

prescription drugs at that store. The Company continues to improve the level

of service it offers and leverage its large and growing base of customers who

opt in as drugstore "members" and who are then entitled to discounts, rebates

and special offers. This strategy, in addition to selling a broader array of

higher margin health, beauty and cosmetic products has increased customer

retention and improved revenue and profitability in this business segment.

Since the beginning of 2009, China Yongxin has signed 12 exclusive

distribution agreements for high margin pharmaceutical products within Jilin

province with several well-known pharmaceutical manufacturers including

Tianjin Smith Kline and French Laboratories Ltd. As of June 30, 2009, China

Yongxin has approximately 216 drugs with exclusive distribution rights in

Jilin province. This portfolio is a key component of its long-term growth

strategy to leverage the large distribution center and channels established to

drive incremental future revenue growth. These agreements are typically one

year in duration and are renewable.

[Bobwins]

Q4 was pretty healthy at .055eps( using higher share count). So if they can maintain that pace in 2010, you are looking at fwd eps of .22. Pretty cheap vs .62.

Retail drug distribution is the key. Chinese government is changing distribution away from hospitals to retail pharmacies. Establishing branded retail chains in big population centers will be the key to profits from drugs that the government is covering.

These are very small drug stores but should grow in sales and profits over time.

Bfar.ob is similar but CFO just left and they replaced CPA firm so question marks there.

[Bobwins]

Q4 was pretty healthy at .055eps( using higher share count). So if they can maintain that pace in 2010, you are looking at fwd eps of .22. Pretty cheap vs .62.

Retail drug distribution is the key. Chinese government is changing distribution away from hospitals to retail pharmacies. Establishing branded retail chains in big population centers will be the key to profits from drugs that the government is covering.

These are very small drug stores but should grow in sales and profits over time.

Bfar.ob is similar but CFO just left and they replaced CPA firm so question marks there.

[ihtblr]

That means about 6 times trailing PE. BSPM, CKGT, CHME all look cheaper.

Do they have any significant production ramp? What is their moat?


TIA


>>>>

10K out. Made .15eps for 2009. Made .09 in Q4. Price should move up. BUT forgot that they had converted huge amount of convertible debt so share count has jumped from 35million they used to calculate FD share count in 10K to 56million currently. Drops eps to more like .09eps for 2009 vs .13 for 2008.

[Stream205]

Rabbit out of the hat ?


Report looks pretty good.

Pleased with that news

[Bobwins]

10K out. Made .15eps for 2009. Made .09 in Q4. Price should move up. BUT forgot that they had converted huge amount of convertible debt so share count has jumped from 35million they used to calculate FD share count in 10K to 56million currently. Drops eps to more like .09eps for 2009 vs .13 for 2008.

[10bags]

nice info thanx

[Bobwins]

http://biz.yahoo.com/e/100126/cyxn.ob8-k.html

http://www.sec.gov/Archives/edgar/data/1087848/000114420410013190/v177261_sc13d.htm

http://www.sec.gov/Archives/edgar/data/1087848/000114420410013185/v177260_sc13d.htm

http://www.sec.gov/Archives/edgar/data/1087848/000114420410009281/v175157_def14c.htm

[10bags]

hey bob you have a source for the dillution?

[Bobwins]

There is big dilution due to the conversion of convertible debt recently. Be sure to factor that in. Also did a very cheap PP.

Another stock to compare CYXN.ob to is Bfar.ob. Both have retail chains as well as manufacturing and distribution.

Bobwins

[10bags]

and will look to the chart

[10bags]

will do my dd here

[10bags]

plan to open 18 more stores wow

[10bags]

watching here